Taletrectinib in <i>ROS1</i> + Non–Small Cell Lung Cancer: TRUST
Taletrectinib showed a high response rate with durable responses, robust IC activity, prolonged PFS, favorable safety, and low rates of neurologic adverse events in TKI-naïve and pretreated patients.
Authors
- Nathan A. Pennell (ORCID: https://orcid.org/0000-0002-1458-0064)
- Huijie Fan (ORCID: https://orcid.org/0000-0003-4298-0679)
- Filippo de Braud (ORCID: https://orcid.org/0000-0003-0103-730X)
- Rose Lai (ORCID: https://orcid.org/0000-0003-4883-7814)
- Caicun Zhou (ORCID: https://orcid.org/0000-0002-1072-9941)
- Lyudmila Bazhenova (ORCID: https://orcid.org/0000-0001-8764-4359)
- Shuanglian Li
- M. Pérol
- Misako Nagasaka (ORCID: https://orcid.org/0000-0001-5308-615X)
- Fei-Wu Ran (ORCID: https://orcid.org/0000-0002-7478-8430)
- Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
- Yuichiro Ohe (ORCID: https://orcid.org/0000-0002-6137-073X)
- Wenfeng Chen (ORCID: https://orcid.org/0000-0002-9507-1711)
- Geoffrey Liu (ORCID: https://orcid.org/0000-0002-2603-7296)
- Yongchang Zhang (ORCID: https://orcid.org/0000-0002-6829-7176)
- Wei Li (ORCID: https://orcid.org/0000-0001-7960-0372)
- Xianyu Zhang (ORCID: https://orcid.org/0000-0002-9738-2361)
- Xicheng Wang (ORCID: https://orcid.org/0000-0002-2719-2538)
- Anwen Xiong
Institutions
- Tongji University (CN)
- Cleveland Clinic (US)
- Central South University (CN)
- University of Toronto (CA)
- University of Milan (IT)
- Guangdong Pharmaceutical University (CN)
- University of California, Irvine (US)
- Princess Margaret Cancer Centre (CA)
- University of California San Diego (US)
- Hunan Cancer Hospital (CN)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Shanghai Pulmonary Hospital (CN)
- Vall d'Hebron Hospital Universitari (ES)
- Shanghai East Hospital (CN)
- Tokyo National Hospital (JP)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1200/jco-25-00275
- Citations
- 30
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 45.55